InvestorsHub Logo
Followers 48
Posts 12067
Boards Moderated 0
Alias Born 09/12/2017

Re: moneycrew post# 133500

Monday, 12/14/2020 7:25:10 PM

Monday, December 14, 2020 7:25:10 PM

Post# of 233739
Progenics spent over $200 million on leronlimab before the sale to CytoDyn a drug that was essentially tossed in the garbage heap
https://talkmarkets.com/content/is-there-a-light-at-the-end-of-the-tunnel-for-a-covid-19-therapeutic?post=284999

And what about Cytolin®???

"We believe that adding PRO 140 to our pipeline of potential anti-viral therapeutics along with Cytolin®, which we are already developing, will position the Company as one of the leading companies in the development of monoclonal antibody-based therapies for HIV/AIDS," commented Gregory A. Gould, Chairman of the Board. "We intend to move forward with the necessary clinical trials to bring both of these potential treatments for HIV to market; and, if we are successful in the development of one or both of these therapies, this could lead to a paradigm shift in the treatment of HIV/AIDS with significant benefits for patients worldwide."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News